Overall, this data further validates the role that AXL plays as a therapeutic target against adaptive resistance in FLT3/ITD AML patients and highlights the potential for the combination of AXL and FLT3 inhibitors to improve clinical outcomes. Here, FLT3 is linked to acute myeloid leukemia.